• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Stock Trend Alerts

Essential Market Ideas and Investing Strategies

  • Newsletter Reviews
  • Hot Stocks
  • Technology
  • Financial News
  • Secrets of the Pros
  • Analysis
Home » 3 Stocks to “Buy the Dip” for Massive Gains

3 Stocks to “Buy the Dip” for Massive Gains

You've no doubt heard the investing adage to “buy the dip.” But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea.

On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run. Here are three stocks more than 25% off their 2021 highs that could still make you rich.

1. Editas Medicine

Editas Medicine (NASDAQ:EDIT) delivered a sizzling gain of 137% last year. However, that sizzle has definitely fizzled in recent months. The biotech stock has plunged 55% from its high set in early January.

You can blame musical chairs in Editas' executive ranks for much of its decline. In January, Chief Scientific Officer Charles Albright left the company. Less than a month later, board Chairman Jim Mullen replaced Cynthia Collins as CEO.

Don't count Editas out, though. The company expects to report results from its early-stage clinical study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis 10 later this year. It recently kicked off a phase 1/2 study of EDIT-301 in treating sickle cell disease. Editas plans to file for U.S. Food and Drug Administration (FDA) approval by the end of 2021 to advance EDIT-301 into clinical testing targeting another rare genetic blood disorder, beta-thalassemia.

If either of its lead candidates proves to be successful in clinical studies, Editas could easily regain and overtake its previous highs. Over the long run, the company's CRISPR gene editing technology could be used to treat many other genetic diseases as well as cancer. Editas is a risky stock, but one that could still be a massive winner.

[Wall Street Insider: Why April 30th Could Spark The Greatest “MegaTrend” of The Decade]

2. Brookfield Renewable

I really expected that Brookfield Renewable (NYSE:BEPC) would take off in 2021. The Biden administration has made clean energy a top priority. Brookfield Renewable is a leader in renewable energy. However, the stock has fallen 27% from its high earlier this year.

What happened? The company's parent, Brookfield Asset Management, sold 15 million shares of Brookfield Renewable in a secondary public offering. This action sparked the renewable-energy stock's decline.

Brookfield Renewable's prospects remain as bright as ever, though. The company expects that a whopping $100 trillion will be spent on reducing carbon emissions over the next three decades. That should translate to strong growth for renewable power.

The company's current capacity stands at 19 gigawatts. Brookfield Renewable's development pipeline could add another 23 gigawatts of capacity. I still think this stock will take off in a major way in the not-too-distant future.

[Trend Alert: Three of the World’s Richest Billionaires Are Quietly Piling Into THIS]

3. Trupanion

Trupanion's (NASDAQ:TRUP) shares more than tripled last year. The story for the pet medical insurance provider hasn't been so great in 2020 so far, though, with its shares tumbling 39% from the peak in February.

The primary culprit behind Trupanion's dismal performance was its Q4 update. The company posted a net loss of $0.09 per share, which was much worse than the consensus analysts estimate of a net loss of $0.03 per share.

However, Trupanion should deliver strong growth. It expects total revenue in 2021 to jump 32% year over year, with subscription revenue increasing by 25%. The company's bottom line might not improve as much, but it's because Trupanion plans to increase investments in new products and international expansion. This higher spending should pay off over the long term.

Trupanion's partnership with Aflac should also begin to reap returns beginning in 2022. The big supplement insurance company plans to offer Trupanion's pet insurance to its large and medium-sized businesses first. In 2023, the two companies hope to expand their focus to the small-business market.

The opportunities for growth in pet medical insurance are huge, with a market penetration rate in the U.S. of around 1%. I don't think Trupanion's slump will last for too much longer. The current pullback looks like a great time to buy this stock and hold it to obtain tremendous returns over the next few years.

[Exclusive: Democrat’s Closed Door Meeting is Set to Ignite Stock Market Boom]

Keith Speights owns shares of Brookfield Renewable Corporation, Editas Medicine, and Trupanion. The Motley Fool owns shares of and recommends Brookfield Asset Management, Editas Medicine, and Trupanion. The Motley Fool recommends Aflac and BROOKFIELD ASSET MANAGEMENT INC. CL.A LV. The Motley Fool has a disclosure policy.

Read more from Keith Speights at Fool.com

You Might Also Like...

  • Will the Global Chip Shortage Mean Boom or Bust for these Silicon Stocks?
  • Profit from the Global Transition to Electric Vehicles with these 5 Penny Stocks
  • The 4 Top Artificial Intelligence Stocks as Demand Continues to Soar
  • Economic Recovery Sets the Stage for this Trio of Value Stocks to Outperform

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe to Stock Trend Alerts

By submitting your email address, you give Stock Trend Alerts permission to deliver investment research to your email inbox. Privacy Policy | How It Works

Popular Posts

  • Martin Weiss Docket No. OP–1670: 12 Inflation-Beating Stocks
  • Jim Rickards – The Return of American Energy: Profit from the Green Lie
  • Louis Navellier Growth Investor: Secure Your Savings From The CBDC
  • Biden’s Big Blackout: Jim Rickards’ Strategic Intelligence Review
  • Marc Lichtenfeld Oxford Income Letter: The #1 Oil and Gas Income Play for 2023
  • Dan Ferris Report: The Only Stocks That Can Safely 8X Your Money During America’s “Dead-Zone”
  • Eric Fry’s Investment Report: The Revenge of the Heartland #1 AI Powered EV Stock
  • Marc Chaikin Reveals Biggest Stock Prediction of his 50-year Career on Wall Street

Recent Posts

  • Dylan Jovine Search & Destroy: 3 AI Software Stocks Revolutionizing Warfare
  • Alpha Investor Charles Mizrahi: Energy Fortunes No. 1 Stock Recommendation
  • Luke Lango’s Innovation Investor: Area 52 The Quantum Windfall Report
  • Nick Black Digital Fortunes Network: Four Digital Pyramid Stocks for Generational Wealth
  • Review: Porter Stansberry and The Big Secret on Wall Street – The Forever Term

Topics

AAPL Advertorial Amazon AMZN Artificial Intelligence Battery Bear Market Biotech Bitcoin Blockchain Clean Energy Cloud Computing Coronavirus COVID Creative Cryptocurrency Dividends E-Commerce Electric Vehicles Elon Musk Energy Ethereum Gold Growth Stocks Inflation Interest Rates International Jeff Brown Louis Navellier Market Crash MSFT Oil and Gas Options Prediction President Biden Recession Retirement Russia Semiconductor Supply Chain Tesla The Fed TSLA Volatility Warren Buffett

Copyright © 2023 · Stock Trend Alerts - Essential Market Moves and Investing Ideas

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

Stock Trend Alerts, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company is not affiliated with, nor does it receive compensation from, any specific security.

To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

About Us | How it Works | Privacy Policy | Terms and Conditions | Contact Us